tetano
Editor, Senior Moderator
World J Virol
. 2021 Nov 25;10(6):312-325.
doi: 10.5501/wjv.v10.i6.312.
COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review
Valentina Bonuomo[SUP] 1 [/SUP], Isacco Ferrarini[SUP] 1 [/SUP], Michele Dell'Eva[SUP] 1 [/SUP], Eugenio Sbisà[SUP] 1 [/SUP], Mauro Krampera[SUP] 1 [/SUP], Carlo Visco[SUP] 2 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection now has a global resonance and represents a major threat for several patient populations. Observations from initial case series suggested that cancer patients in general might have an unfavorable outcome following coronavirus disease 2019 (COVID-19), due to their underlying conditions and cytotoxic treatments. More recently, data regarding the incidence and clinical evolution of COVID-19 in lymphomas have been reported with the aim to identify those more frequently associated with severe complications and death. Patients with lymphoma appear particularly vulnerable to SARS-CoV-2 infection, only partly because of the detrimental effects of the anti-neoplastic regimens (chemotherapy, pathway inhibitors, monoclonal antibodies) on the immune system. Here, we systematically reviewed the current literature on COVID-19 in adult patients with lymphoma, with particular emphasis on disease course and prognostic factors. We also highlighted the potential differences in COVID-19 clinical picture according to lymphoma subtype, delivered treatment for the hematological disease and its relationship on how these patients have been managed thus far.
Keywords: Bendamustine; COVID-19; Hematological malignancies; Lymphoma; Rituximab; SARS-CoV-2 infection.
. 2021 Nov 25;10(6):312-325.
doi: 10.5501/wjv.v10.i6.312.
COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review
Valentina Bonuomo[SUP] 1 [/SUP], Isacco Ferrarini[SUP] 1 [/SUP], Michele Dell'Eva[SUP] 1 [/SUP], Eugenio Sbisà[SUP] 1 [/SUP], Mauro Krampera[SUP] 1 [/SUP], Carlo Visco[SUP] 2 [/SUP]
Affiliations
- PMID: 34909405
- PMCID: PMC8641038
- DOI: 10.5501/wjv.v10.i6.312
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection now has a global resonance and represents a major threat for several patient populations. Observations from initial case series suggested that cancer patients in general might have an unfavorable outcome following coronavirus disease 2019 (COVID-19), due to their underlying conditions and cytotoxic treatments. More recently, data regarding the incidence and clinical evolution of COVID-19 in lymphomas have been reported with the aim to identify those more frequently associated with severe complications and death. Patients with lymphoma appear particularly vulnerable to SARS-CoV-2 infection, only partly because of the detrimental effects of the anti-neoplastic regimens (chemotherapy, pathway inhibitors, monoclonal antibodies) on the immune system. Here, we systematically reviewed the current literature on COVID-19 in adult patients with lymphoma, with particular emphasis on disease course and prognostic factors. We also highlighted the potential differences in COVID-19 clinical picture according to lymphoma subtype, delivered treatment for the hematological disease and its relationship on how these patients have been managed thus far.
Keywords: Bendamustine; COVID-19; Hematological malignancies; Lymphoma; Rituximab; SARS-CoV-2 infection.